Intrathecal Pumps Market Size, Share & Trends Analysis Report By Type (Baclofen, Morphine, Clonidine), By Application (Pain, Spasticity), By Region (North America, APAC), And Segment Forecasts, 2022 - 2030

Report Overview

The global intrathecal pumps market size was valued at USD 325.6 million in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 5.2% from 2022 to 2030.  The rising incidence of chronic disorders, such as cancer, back pain, and chronic pancreatitis, is the major factor anticipated to drive the industry's growth. For instance, according to the National Cancer Institute, in January 2019, there were around 16.9 million cancer-affected patients across the U.S. Thus, escalating cancer cases are expected to create robust growth opportunities. Technological advancements in intrathecal pumps are expected to augment industry growth. Advancements, such as improvements in pump delivery modes, catheter design, as well as safety features, are predicted to increase its adoption rate.

The COVID-19 pandemic moderately impacted industry growth. Pandemic-induced social and healthcare disruptions may pose a substantial risk to patients with an intrathecal pump that may miss replacement or refill appointments, resulting in severe withdrawal syndrome impelling the industry growth. In the case of baclofen, this may be life‐threatening with complications, such as seizure, rhabdomyolysis, coma, and death, creating a challenge in the industry. An increasing number of product launches by prominent companies is estimated to boost industry growth. In June 2022, Amneal Pharmaceuticals announced the launch of LYVISPAH (baclofen) for the treatment of spasticity associated with multiple sclerosis and other spinal cord disorders.

In addition, manufacturers of intrathecal pumps are also observed to advance devices having longer battery life, which may help minimize the number of future surgical procedures required to replace expiring pumps. Rising cases of pain disorders are projected to drive the industry's growth. With the rising survival rate for oncologic patients, the occurrence of cancer pain is also growing. Pain arises in 67% of patients with metastatic cancer and is among the most prevalent symptoms. The majority of chronic cancer pain can be managed with pharmacologic therapies including analgesia. However, intrathecal drug delivery offers an alternative route of administration for analgesics, which helps in reducing side effects with better bioavailability, thereby, accelerating the industry growth.

Type Insights 

The morphine segment accounted for the largest revenue share of more than 31.00% in 2021. Morphine is considered the gold standard in intrathecal drug administration owing to its strong receptor affinity, stability, and extensive user experience of the drug. Additionally, morphine has received approval for long-term intrathecal pain treatment by the U.S. FDA. Furthermore, long-term intrathecal morphine has fewer side effects as compared to systemic opioids, expecting to spur the growth of this segment. Bupivacaine is expected to grow at a healthy CAGR of 6.6% over the forecast period. Bupivacaine is considered an excellent adjunct medication in intrathecal therapy.

Several studies have revealed that bupivacaine synergistically improves the effect of the intrathecal opioids when used in combination, significantly contributing to its growing market share. Bupivacaine allows some patients to reduce their oral opioid usage, as well as minimizes dose escalations of intrathecal opioids. Thus, several advantages associated with bupivacaine are anticipated to secure the segment growth. The baclofen type segment is expected to experience a substantial growth rate during the forecast period. Intrathecal baclofen is useful in treating spasticity and pain as well as multiple types of central pain including SCI, post-stroke, and musculoskeletal pain. Thus, the rising prevalence of pain and spasticity is expected to contribute to segment growth.

Application Insights

On the basis of applications, the global industry has been further bifurcated into pain and spasticity. The pain application segment dominated the industry and accounted for the largest share of more than 70.00% of the global revenue in 2021. The rising prevalence of chronic and acute disorders, such as chronic pain cancer, and other pain-causing ailments, such as failed back surgery syndrome, is one of the key factors enhancing the segment growth. Hence, intrathecal pumps are best suited for individuals suffering from pain-associated disorders. The spasticity segment is expected to witness a significant growth rate from 2022 to 2030.

Several market players are focusing on developing products for the treatment of spasticity. For instance, Medtronic’s Intrathecal Baclofen Therapy (ITB) is a treatment that uses Lioresal Intrathecal (baclofen) to be distributed into the fluid around an individual’s spinal cord to manage severe spasticity. In addition, rising cases of stroke across the world are one of the major factors contributing to the segment growth. For instance, as per a report published by the American College of Cardiology Foundation in 2019, in every 40 seconds, on average, an American suffers from a stroke and around 795,000 Americans have recurrent & new strokes annually.

Regional Insights

North America region held over 40.5% largest market share in 2021. The availability of well-developed primary, secondary, and tertiary care hospitals supported the market growth in the North American region. Moreover, a strong reimbursement network, and favorable government funding, are major factors predicted to foster market growth. The rising collective efforts by key market companies to improve their product portfolio and ensure high-quality standards are expected to surge the demand for intrathecal pumps across this region.

Asia Pacific is expected to grow at the fastest CAGR of 7.0% during the forecast period. The presence of a large patient pool in the Asia Pacific is expected to boost the product demand. An increasing number of pain care centers in China, Singapore, Japan, and India is expected to boost the adoption of intrathecal pumps. For instance, Singapore Pain Care Center (SPCC) is a pain management center in Southeast Asia that provides an alternative to open surgery. The high prevalence of pain-related disorders, increasing R&D expenditure, and the growing number of pain care centers in the U.S. & Canada contributed considerably to the region’s growth. The prevalence of cancer in the U.S. continues to rise at a rapid pace, creating an increased demand for effective and advanced intrathecal pumps.

According to the American Cancer Society, it was estimated that around 1.8 million new cases of cancer were to be diagnosed across the U.S. in 2020. In addition, the increasing prevalence of back pain is projected to create growth opportunities for intrathecal pumps. For instance, according to the American Chiropractic Association, around 80% of the population will experience back pain at some time in their entire life. Europe is expected to experience a significant growth rate during the analysis period. Rising investments in healthcare infrastructure are expected to boost the product demand in various pain care centers, thereby driving the regional market growth.

Key Companies & Market Share Insights

Key companies are focusing on developing strategic growth initiatives, such as mergers, product launches, and partnerships, to gain a competitive edge. In October 2019, Flowonix Medical received approval from FDA for Prometra II 40 ml programmable pump for use with intrathecal baclofen. This product launch allowed the company to provide a Prometra system to serve 40 ml pumps to cancer patients. The industry players are adopting various strategies, such as mergers & acquisitions, new product developments, joint ventures, and partnerships, to maintain a strong foothold in the global market. For instance, in January 2018, Medtronic received FDA approval for a novel clinician programmer for use with SynchroMed (TM)II intrathecal drug delivery system. Some of the leading players in the global intrathecal pumps market include:

• Medtronic plc

• Codman & Shurtleff

• Medallion Therapeutics

• Tricumed GmbH

• Arrow International Inc.

Intrathecal Pumps Market Report Scope

Global Intrathecal Pumps Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global intrathecal pumps market report based on type, application, and region:

• Type Outlook (Revenue, USD Million, 2017 - 2030)

  • Baclofen

  • Bupivacaine

  • Clonidine

  • Morphine

  • Ziconotide

  • Others

• Application Outlook (Revenue, USD Million, 2017 - 2030)

  • Spasticity

  • Pain

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE